olaparib,bevacizumab
Merck,roche,AstraZeneca
['paola1', 'ovarian']
important overall survival data in ovarian cancer from paola1 in esmo2022. first time ever that a maintenance treatment in first line showed a benefit in os vs an active control arm! 